Global Study Looking at the Combination of RAD001 and Sorafenib to Treat Patients With Advanced Hepatocellular Carcinoma

NCT00828594 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

130

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatocellular Carcinoma

Interventions

DRUG: RAD001
DRUG: RAD001, sorafenib

Sponsor

Novartis Pharmaceuticals